Fennec Pharmaceuticals (FENC) vs Kyverna Therapeutics (KYTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Fennec Pharmaceuticals (FENC) has outperformed Kyverna Therapeutics (KYTX) over the past year, gaining 15.3% versus a loss of 13.9%. Kyverna Therapeutics is the larger company by market cap ($382.2 million vs $372.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FENC | KYTX |
|---|---|---|
| Share price | $10.63 | $6.18 |
| Market cap | $372.76M | $382.19M |
| 1-day change | +2.61% | +0.16% |
| YTD return | +38.05% | -34.26% |
| 1-year return | +15.29% | -13.93% |
| 5-year return | +15.67% | — |
| Forward P/E | 11.21 | — |
| EPS (TTM) | $-0.12 | $-2.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.25 | $13.67 |
| 52-week low | $5.65 | $5.96 |
| Distance from 52-week high | -19.77% | -54.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +66.23% | +391.91% |
| Average volume | 193.13K | 903.83K |
| Shares outstanding | 35.07M | 61.84M |
| Employees | 35 | 149 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FENC has outperformed KYTX by 29.2 percentage points over the past year.
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 149 employees
FENC vs KYTX FAQ
Which is bigger, Fennec Pharmaceuticals or Kyverna Therapeutics?
Kyverna Therapeutics (KYTX) is larger, with a market capitalization of $382.19M compared with $372.76M for Fennec Pharmaceuticals (FENC).
Which stock has performed better over the past year, FENC or KYTX?
FENC returned +15.29% over the past 12 months, compared with -13.93% for KYTX (price return, excluding dividends). Past performance does not predict future results.
Are Fennec Pharmaceuticals and Kyverna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.